 | This article has multiple issues. Please helpimprove it or discuss these issues on thetalk page.(Learn how and when to remove these messages) (Learn how and when to remove this message)
|
 | |
 | |
Native name | エーザイ株式会社 |
|---|---|
Romanized name | Ēzai kabushiki gaisha |
| Company type | PublicKK |
| TYO:4523 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component | |
| Industry | Pharmaceuticals |
| Founded | December 6, 1941; 84 years ago (1941-12-06) |
| Founder | Toyoji Naito |
| Headquarters | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |
Key people | Haruo Naito (President andCEO) |
| Products | |
| Revenue |  ¥ 741.8 billion (2023)[1] |
| ¥ 53.4 billion (2023)[1] | |
| ¥ 43.8 billion (2023)[1] | |
| Total assets | ¥ 743.9 billion (2023)[1] |
| Total equity | ¥ 430.2 billion (2023)[1] |
| Owner | The Master Trust Bank of Japan(11.78%) Japan Trustee Services Bank(10.99%) Nippon Life(4.29%)[2] |
Number of employees | 10,000 (2023)[1] |
| Website | Official website |
| Footnotes / references [2][1] | |
Eisai Co., Ltd. (Japanese:エーザイ株式会社,Hepburn:Ēzai Kabushiki-gaisha) is a Japanesepharmaceutical company headquartered inTokyo, Japan. It has some 10,000 employees, among them about 1,500 in research.Eisai is listed on theTokyo Stock Exchange and is a member of theTopix 100 andNikkei 225stock indices.[3]
Nihon Eisai Co. Ltd. was established in 1941.[4] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[5] The American subsidiary of the company, Eisai Inc., was established in 1995.[6]
On November 25, 1996, Eisai receivedapproval from the United StatesFood and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed withPfizer.[7]
Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed withJohnson & Johnson.
In September 2006, the company acquired four oncology products fromLigand Pharmaceuticals.[8]
In April 2007, Eisai acquiredExton, Pennsylvania-based Morphotek, a company developingtherapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.
In December 2007, Eisai acquiredMGI Pharma, a company specializing in oncology, for US$3.9 billion.[9] This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.
In 2009, Eisai received the Corporate Award from theNational Organization for Rare Disorders (NORD) for the development of Banzel (rufinamide).[10]
In June 2023, the company suffered from aransomware attack, causing a shutdown of some of its logistical systems.[11]
Lecanemab, branded as "Leqembi" was approved by the U.S. Food and Drug Administration (FDA) in January 2023 under an Accelerated Approval pathway.[12] The approval was converted into a traditional approval in July 2023.[13]
Eisai Co., Ltd. is based inTokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered inNutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO.[14] Eisai maintainsmedical research headquarters in Nutley as well as at locations inJapan, theUnited Kingdom, the Research Triangle inNorth Carolina, andMassachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.[15][16]
The company has manufacturing sites in Japan,North Carolina (USA),Maryland (USA),Bogor (Indonesia),Suzhou (China),Tainan (Taiwan),Visakhapatnam (India) andHatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.
Some of the key products that Eisai produces or markets with partners include:
Aricept accounted for 40% of Eisai's revenue as of March 2010.[17] The main competitor to Aricept is a generic formulation fromRanbaxy Labs.[17] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[17]
| International | |
|---|---|
| National | |
